Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
第一作者:
Sreeraj,Macha
第一单位:
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA. smacha@rdg.boehringeringelheim.com
作者:
医学主题词
吸收(Absorption);投药, 口服(Administration, Oral);动物(Animals);抗HIV药(Anti-HIV Agents);胆汁(Bile);生物转化(Biotransformation);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物相互作用(Drug Interactions);女(雌)性(Female);HIV蛋白酶抑制药(HIV Protease Inhibitors);注射, 静脉内(Injections, Intravenous);男(雄)性(Male);氧化还原(Oxidation-Reduction);吡啶类(Pyridines);吡喃酮类(Pyrones);大鼠(Rats);大鼠, Sprague-Dawley(Rats, Sprague-Dawley);利托纳韦(Ritonavir);性别因素(Sex Factors);磺胺类(Sulfonamides);组织分布(Tissue Distribution)
DOI
10.1211/jpp.59.9.0006
PMID
17883893
发布时间
2020-12-09
- 浏览12
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



